Session » (2195–2226) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III: SpA

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 2211

A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort

9:00AM-11:00AM: Abstract Number: 2210

Antibodies to Four Novel Peptides in New Onset Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2222

Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides

9:00AM-11:00AM: Abstract Number: 2208

Awareness and Attitudes Regarding Axial Spondyloarthritis Among Non-Rheumatology Physicians in the United States

9:00AM-11:00AM: Abstract Number: 2215

Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort

9:00AM-11:00AM: Abstract Number: 2221

Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers

9:00AM-11:00AM: Abstract Number: 2219

Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2202

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers

9:00AM-11:00AM: Abstract Number: 2197

Diagnostic Delay in Patients Included in the International Map of Axial Spondyloarthrtis: Associations with Geographic, Socio-demographic and Disease-related Factors

9:00AM-11:00AM: Abstract Number: 2224

Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes

9:00AM-11:00AM: Abstract Number: 2205

Disease Activity and Widespread Pain Are the 2 Key Drivers of Global Health in Axial Spondyloarthritis, with Similar Findings in Different Patient Populations: An Analysis of 4 Databases and 6064 Patients

9:00AM-11:00AM: Abstract Number: 2218

Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2220

Factors Associated with Achieving Remission in Patients with Early Peripheral Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort

9:00AM-11:00AM: Abstract Number: 2196

Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS)

9:00AM-11:00AM: Abstract Number: 2199

Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration

9:00AM-11:00AM: Abstract Number: 2217

Gender Disparities in Disease Activity Scores and Treatment Response Among Patients with Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2216

Hierarchy of Determinants of Work Impairment in Spondyloarthritis: Data from the Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) International Validation Study

9:00AM-11:00AM: Abstract Number: 2226

How Do Spondyloarthritis Start? Identification of the First Signs or Symptoms According to Diagnosis and HLA-B27. Data from REGISPONSER and RESPONDIA Registries

9:00AM-11:00AM: Abstract Number: 2213

Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach

9:00AM-11:00AM: Abstract Number: 2206

Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2212

Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2207

Knowledge, Awareness, and Attitudes Regarding Inflammatory Back Pain Among Non-Rheumatology Physicians in the United States

9:00AM-11:00AM: Abstract Number: 2225

Long-term Evolution of Spondyloarthritis Patients Included in REGISPONSER, 17 Years Later (REGISPON-3 Study)

9:00AM-11:00AM: Abstract Number: 2209

Prevalence and Clinical Characteristics of Late Onset Axial Spondyloarthritis: Results from a Multicentre Nationwide Study

9:00AM-11:00AM: Abstract Number: 2195

Regional Differences in Clinical Phenotype of Axial Spondyloarthritis. Results from the International Map of Axial Spondyloarthritis (IMAS)

9:00AM-11:00AM: Abstract Number: 2223

Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study

9:00AM-11:00AM: Abstract Number: 2204

Residual Disease Activity in Canadian Patients with Axial Spondyloarthritis: Results from a Multi-registry Analysis (UNISON-Axial SpA)

9:00AM-11:00AM: Abstract Number: 2203

Self-Reported and Physician´s Assessment of Inflammatory Back Pain According to ASAS Criteria: Is It the Same?

9:00AM-11:00AM: Abstract Number: 2200

Sensitivity to Change of Structural Outcomes in Early Axial Spondyloarthritis After 10 Years of Follow Up. Data from DESIR Cohort

9:00AM-11:00AM: Abstract Number: 2214

Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis

9:00AM-11:00AM: Abstract Number: 2201

When Usual Care Is Not so Usual: Facing the Challenges of Protocol Violations and Generalisability When Running a Strategy Trial. the Example of the Cluster-Randomized TICOSPA Trial

9:00AM-11:00AM: Abstract Number: 2198

Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].